SCHEMBL3066758

SCHEMBL3066758

CC1CC(=O)CC(C)N1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.69
PSEN1 P49768 5/20 0.69
PSEN2 P49810 5/20 0.69
APH1B Q8WW43 5/20 0.69
NCSTN Q92542 5/20 0.69
APH1A Q96BI3 5/20 0.69
PSENEN Q9NZ42 5/20 0.69
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
MMP2 P08253 1/20 0.49
HSD11B1 P28845 1/20 0.47
ATM Q13315 1/20 0.46
PGR P06401 1/20 0.45
HTT P42858 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 1/20 0.43
AKR1C3 P42330 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3068763 1.00 ACHE (0.69) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL3066755 1.00 ACHE (0.69) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL3068766 1.00 ACHE (0.69) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL14606482 0.86 PSEN1 (0.52) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL5915351 0.84 ACHE (0.87) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL5915290 0.84 ACHE (0.87) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL916819 0.81 PSEN1 (0.57) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL5915359 0.81 ACHE (1.00) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL5250675 0.81 ACHE (1.00) ACHEPSEN1PSEN2APH1BNCSTN
SCHEMBL3192710 0.80 PSEN1 (0.56) ACHEPSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267747-A1 5-(Arylsulfonyl)-Pyrazolopiperidines ELAN PHARMACEUTICALS, INC. (US) 2010-10-21 US disclosed
US-7732609-B2 5-(arylsulfonyl)-pyrazolopiperidines ELAN PHARMACEUTICALS, INC. (US) 2010-06-08 US disclosed
EP-1957458-A2 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES Elan Pharmaceuticals Inc. (US) 2008-08-20 EP disclosed
US-20070155753-A1 5-(Arylsulfonyl)-Pyrazolopiperidines ELAN PHARMACEUTICALS, INC. 2007-07-05 US disclosed
WO-2007064914-A2 5-(ARYLSULFONYL)-PYRAZOLOPIPERIDINES ELAN PHARMACEUTICALS, INC. (US) 2007-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155753-A1 5-(Arylsulfonyl)-Pyrazolopiperidines PSEN1, PSEN2, C1S ACHE 60/4885PSEN1 1/4885PSEN2 2/4885
US-20100267747-A1 5-(Arylsulfonyl)-Pyrazolopiperidines PSEN1, PSEN2, C1S ACHE 60/4885PSEN1 1/4885PSEN2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.